PMID- 38122814
OWN - NLM
STAT- MEDLINE
DCOM- 20240124
LR  - 20240131
IS  - 1743-1328 (Electronic)
IS  - 0161-6412 (Linking)
VI  - 46
IP  - 3
DP  - 2024 Mar
TI  - Minocycline mitigates tau pathology via modulating the TLR-4/NF-small ka, Cyrillicbeta signalling 
      pathway in the hippocampus of neuroinflammation rat model.
PG  - 261-271
LID - 10.1080/01616412.2023.2296754 [doi]
AB  - INTRODUCTION: The neuroinflammatory response was seen to impact the formation of 
      phosphorylated tau protein in Alzheimer's disease (AD). This study aims to 
      investigate the molecular mechanism of minocycline in reducing phosphorylated tau 
      protein formation in the hippocampus of lipopolysaccharide (LPS)-induced rats. 
      METHODS: Fifty adult male Sprague Dawley (SD) rats were randomly allocated to 1 
      of 5 groups: control, LPS (5 mg/kg), LPS + minocycline (25 mg/kg), 
      LPS + minocycline (50 mg/kg) and LPS + memantine (10 mg/kg). Minocycline and 
      memantine were administered intraperitoneally (i.p) for two weeks, and LPS was 
      injected i.p. once on day 5. ELISA was used to determine the level of 
      phosphorylated tau protein in SD rats' hippocampal tissue. The density and 
      expression of Toll-like receptor-4 (TLR-4), nuclear factor 
      kappa-light-chain-enhancer of activated B cells (NF-small ka, Cyrillicbeta), tumour necrosis 
      factor-alpha (TNF-alpha), and cyclooxygenase (COX)-2 were determined using Western 
      blot and immunohistochemistry. RESULTS: Minocycline, like memantine, prevented 
      LPS-induced increasein phosphorylated tau protein level suggested via reduced 
      density and expression of TLR-4, NF-small ka, Cyrillicbeta, TNF-alphaand COX-2 proteins in rat 
      hippocampal tissue. Interestingly, higher doses were shown to be more 
      neuroprotective than lower doses. CONCLUSION: This study suggests that 
      minocycline suppresses the neuroinflammation signalling pathway and decreased 
      phosphorylated tau protein formation induced by LPS in a dose-dependent manner. 
      Minocycline can be used as a preventative and therapeutic drug for 
      neuroinflammatory diseases such as AD.
FAU - Abdo Qaid, Entesar Yaseen
AU  - Abdo Qaid EY
AD  - School of Health Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, 
      Malaysia.
AD  - Histology Department, Faculty of Medicine and Health Sciences, Taiz University, 
      Taiz, Yemen.
FAU - Abdullah, Zuraidah
AU  - Abdullah Z
AD  - School of Health Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, 
      Malaysia.
FAU - Zakaria, Rahimah
AU  - Zakaria R
AD  - Department of Physiology, School of Medical Sciences, Universiti Sains Malaysia, 
      Kubang Kerian, Kelantan, Malaysia.
FAU - Long, Idris
AU  - Long I
AD  - School of Health Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, 
      Malaysia.
LA  - eng
PT  - Journal Article
DEP - 20240122
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - FYY3R43WGO (Minocycline)
RN  - 0 (tau Proteins)
RN  - 0 (Lipopolysaccharides)
RN  - W8O17SJF3T (Memantine)
RN  - 0 (Toll-Like Receptor 4)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (NF-kappa B)
SB  - IM
MH  - Rats
MH  - Animals
MH  - Male
MH  - *Minocycline/pharmacology/therapeutic use
MH  - tau Proteins/metabolism
MH  - Neuroinflammatory Diseases
MH  - Lipopolysaccharides
MH  - Rats, Sprague-Dawley
MH  - Memantine/pharmacology/metabolism
MH  - Toll-Like Receptor 4/metabolism
MH  - Hippocampus/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - *Alzheimer Disease/drug therapy/metabolism
MH  - NF-kappa B/metabolism
OTO - NOTNLM
OT  - Lipopolysaccharide
OT  - hippocampus
OT  - memantine
OT  - minocycline
OT  - neuroinflammation
EDAT- 2023/12/21 00:41
MHDA- 2024/01/24 06:43
CRDT- 2023/12/20 19:12
PHST- 2024/01/24 06:43 [medline]
PHST- 2023/12/21 00:41 [pubmed]
PHST- 2023/12/20 19:12 [entrez]
AID - 10.1080/01616412.2023.2296754 [doi]
PST - ppublish
SO  - Neurol Res. 2024 Mar;46(3):261-271. doi: 10.1080/01616412.2023.2296754. Epub 2024 
      Jan 22.